KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Potassium responses to sodium zirconium cyclosilicate in hyperkalemic hemodialysis patients: post-hoc analysis of DIALIZE.BMC NephrolPMID 35135481PMC88266692022-Feb-080.98未发现恶性肿瘤人群证据。待处理
Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials.J Headache PainPMID 35130836PMC89034902022-Feb-070.98未发现恶性肿瘤人群证据。待处理
Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial.LancetPMID 35093205PMC87970102022-Feb-050.98未发现恶性肿瘤人群证据。待处理
Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study).TrialsPMID 35123553PMC88175332022-Feb-050.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.LancetPMID 35123694PMC88192712022-Feb-050.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.N Engl J MedPMID 35045221PMC116513662022-Feb-030.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.N Engl J MedPMID 35108470无 PMCID2022-Feb-031.00命中用户提供的消化道肿瘤阳性参考集。待处理
Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute study.HaematologicaPMID 34134469PMC88045722022-Feb-010.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome: Open-label, dose-selection, lead-in stage of a phase 3 study.Am J HematolPMID 34724251无 PMCID2022-Feb-010.85This is a primary result report from a randomized Phase III oncology trial (MDS) with a drug intervention. However, it is excluded because the primary efficacy endpoint is a response rate (proportion achieving transfusion independence), not a time-to-event endpoint like OS, PFS, DFS, EFS, RFS, TTP, or any endpoint analyzed via Kaplan-Meier or reported as a hazard ratio.待处理
Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181.J Clin OncolPMID 34730989无 PMCID2022-Feb-010.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies.J Clin OncolPMID 34855460PMC87974872022-Feb-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy of Treatment With Armodafinil for Cancer-Related Fatigue in Patients With High-grade Glioma: A Phase 3 Randomized Clinical Trial.JAMA OncolPMID 34882169PMC86625352022-Feb-010.90The trial is a phase 3 randomized oncology study with a drug intervention and reports original primary results. However, the primary efficacy endpoint is a change in fatigue score, which is not a time-to-event endpoint. The criteria require a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, or a Kaplan-Meier/HR analysis). This study lacks that specific endpoint.待处理
Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine-Refractory Differentiated Thyroid Cancer: The REALITY Randomized Clinical Trial.JAMA OncolPMID 34913959PMC86789012022-Feb-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma.JAMA OncolPMID 34940781PMC88552302022-Feb-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Symptoms of Women With High-Risk Early-Stage Ovarian Cancer.Obstet GynecolPMID 34991145PMC91265682022-Feb-010.95The record is an eligible oncology, human, randomized, Phase III trial with time-to-event analytical methods, but it is excluded because it is a secondary analysis (focused on symptom presentation, not the trial's primary efficacy endpoint) and lacks clear evidence of a drug-containing intervention.待处理
Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.JAMAPMID 35029629PMC88083332022-Feb-010.98未发现恶性肿瘤人群证据。待处理
Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab.BMC CancerPMID 35105329PMC88089922022-Feb-010.45The study is a randomized Phase III oncology trial with a drug intervention (biosimilar bevacizumab) and reports original results, but the primary efficacy endpoint is overall response rate (ORR), not a time-to-event endpoint (e.g., OS, PFS, DFS, HR, Kaplan-Meier). The deterministic review correctly identified the absence of time-to-event signal.待处理
Bimekizumab Self-Injection Devices: Two Multicenter, Randomized, Open-Label Studies on Self-Administration by Patients With Psoriasis.J Drugs DermatolPMID 35133113无 PMCID2022-Feb-010.98未发现恶性肿瘤人群证据。待处理
Effect of S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Plus Oxaliplatin as Perioperative Chemotherapy for Locally Advanced, Resectable Gastric Cancer: A Randomized Clinical Trial.JAMA Netw OpenPMID 35226081PMC88865202022-Feb-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Quality of Life Following Receipt of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer.JAMA Netw OpenPMID 35226083PMC88865462022-Feb-010.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes.Diabetes Obes MetabPMID 34647404PMC92992272022-Feb0.98未发现恶性肿瘤人群证据。待处理
Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trials.J Dermatolog TreatPMID 32347763无 PMCID2022-Feb0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of guselkumab compared with placebo and adalimumab in Korean patients with moderate-to-severe psoriasis: post-hoc analysis from the phase III, double-blind, placebo- and active-comparator-controlled VOYAGE 1/2 trials.J Dermatolog TreatPMID 32419536无 PMCID2022-Feb0.98未发现恶性肿瘤人群证据。待处理
Performance and Predictors of Minimal Disease Activity Response in Patients With Peripheral Spondyloarthritis Treated With Adalimumab.Arthritis Care Res (Hoboken)PMID 32937016无 PMCID2022-Feb0.98未发现恶性肿瘤人群证据。待处理
Modeling Endoscopic Improvement after Induction Treatment With Mesalamine in Patients With Mild-to-Moderate Ulcerative Colitis.Clin Gastroenterol HepatolPMID 33279779PMC85889932022-Feb0.98未发现恶性肿瘤人群证据。待处理
Assessment of risk compensation following use of the dapivirine vaginal ring in southwestern Uganda.Sex Transm InfectPMID 33542153PMC87850552022-Feb0.98未发现恶性肿瘤人群证据。待处理
Recanalization after cerebral venous thrombosis. A randomized controlled trial of the safety and efficacy of dabigatran etexilate versus dose-adjusted warfarin in patients with cerebral venous and dural sinus thrombosis.Int J StrokePMID 33724104无 PMCID2022-Feb0.98未发现恶性肿瘤人群证据。待处理
Sustained-release isosorbide mononitrate as adjuvant treatment in isolated systolic hypertension in the elderly.J Hum HypertensPMID 33850272无 PMCID2022-Feb0.98未发现恶性肿瘤人群证据。待处理
Clinical Characteristics and Outcomes of Eyes with Intraocular Inflammation after Brolucizumab: Post Hoc Analysis of HAWK and HARRIER.Ophthalmol RetinaPMID 33971353无 PMCID2022-Feb0.98未发现恶性肿瘤人群证据。待处理
Willingness of Women with Endometriosis Planning to Undergo IVF to Participate in a Randomized Clinical Trial and the Effects of the COVID-19 Pandemic on Potential Participation.Reprod SciPMID 34363198PMC83459052022-Feb0.98未发现恶性肿瘤人群证据。待处理
Population Pharmacokinetics of Tadalafil in Pediatric Patients with Pulmonary Arterial Hypertension: A Combined Adult/Pediatric Model.Clin PharmacokinetPMID 34379314PMC88137052022-Feb0.98未发现恶性肿瘤人群证据。待处理
Randomized trial of two maintenance doses of vitamin D in children with chronic kidney disease.Pediatr NephrolPMID 34392411无 PMCID2022-Feb0.98未发现恶性肿瘤人群证据。待处理
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk.Prostate Cancer Prostatic DisPMID 34420037无 PMCID2022-Feb0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Pharmacokinetics and Exposure-Response of Vosoritide in Children with Achondroplasia.Clin PharmacokinetPMID 34431071PMC88137072022-Feb0.98未发现恶性肿瘤人群证据。待处理
Dosing Regimen Prediction and Confirmation With Rivaroxaban for Thromboprophylaxis in Children After the Fontan Procedure: Insights From the Phase III UNIVERSE Study.J Clin PharmacolPMID 34524700PMC93039332022-Feb0.98未发现恶性肿瘤人群证据。待处理
Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYOND.J RheumatolPMID 34526397无 PMCID2022-Feb0.98未发现恶性肿瘤人群证据。待处理
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.Lancet Infect DisPMID 34534511PMC84396212022-Feb0.95Eligible on human, randomized, phase 3, drug intervention, and original result criteria, but excluded because it is not an oncology trial and lacks the required time-to-event efficacy endpoint.待处理
A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis.Kidney IntPMID 34560137无 PMCID2022-Feb0.98未发现恶性肿瘤人群证据。待处理
Randomised controlled trial showed long-term efficacy, immunogenicity and safety of varicella vaccines in Norwegian and Swedish children.Acta PaediatrPMID 34606114PMC92979352022-Feb0.98未发现恶性肿瘤人群证据。待处理
Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients.Br J CancerPMID 34616010PMC87707032022-Feb0.85The record is from a secondary analysis of genome-wide association data from multiple phase III randomized oncology trials, but it does not report survival, progression, recurrence, death, hazard, or other time-to-event efficacy outcomes required for inclusion.待处理
Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.J Eur Acad Dermatol VenereolPMID 34634163PMC92979652022-Feb0.98未发现恶性肿瘤人群证据。待处理
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.J Thorac OncolPMID 34648948无 PMCID2022-Feb0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Exposure-Response Analyses of Letermovir Following Oral and Intravenous Administration in Allogeneic Hematopoietic Cell Transplantation Recipients.Clin Pharmacol TherPMID 34674258无 PMCID2022-Feb0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306).BJOGPMID 34676663PMC92994542022-Feb0.98未发现恶性肿瘤人群证据。待处理
Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study.Clin Lymphoma Myeloma LeukPMID 34686445无 PMCID2022-Feb0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy of a novel device for cryoprevention of oral mucositis: a randomized, blinded, multicenter, parallel group, phase 3 trial.Bone Marrow TransplantPMID 34728786PMC88210132022-Feb0.95The trial is a randomized, blinded, Phase III oncology trial in humans with original results, but it evaluates a cooling device (device vs. ice) and does not include a drug-containing intervention. The primary endpoint is a patient-reported symptom score (Oral Mucositis Assessment Scale), not a time-to-event efficacy endpoint like OS, PFS, or similar.待处理
Nonsteroidal anti-inflammatory drug-sparing effect of secukinumab in patients with radiographic axial spondyloarthritis: 4-year results from the MEASURE 2, 3 and 4 phase III trials.Rheumatol IntPMID 34773130无 PMCID2022-Feb0.98未发现恶性肿瘤人群证据。待处理
Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial.Lancet Respir MedPMID 34774185PMC85854892022-Feb0.98未发现恶性肿瘤人群证据。待处理
Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes.Transplant Cell TherPMID 34775146PMC88823462022-Feb0.85The report describes a Phase III randomized trial with human oncology patients and time-to-event endpoints (PFS, OS), but the intervention is transplantation with graft types (UCB, Haplo-BM), not a drug-containing regimen. The inclusion criteria require a drug-containing intervention, which is not explicitly established here.待处理
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.Lancet Gastroenterol HepatolPMID 34798038无 PMCID2022-Feb0.95Study is a Phase III randomized trial of etrolizumab vs. infliximab in ulcerative colitis (a non-malignant inflammatory bowel disease). The primary endpoint is clinical response/remission, not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.).待处理